Literature DB >> 25487973

Immunization with recombinant Pb27 protein reduces the levels of pulmonary fibrosis caused by the inflammatory response against Paracoccidioides brasiliensis.

Elis Araujo Morais1, Estefânia Mara do Nascimento Martins, Jankerle Neves Boelone, Dawidson Assis Gomes, Alfredo Miranda Goes.   

Abstract

Paracoccidioidomycosis (PCM) is a systemic mycosis in which the host response to the infectious agent typically consists of a chronic granulomatous inflammatory process. This condition causes lesions that impair lung function and lead to chronic pulmonary insufficiency resulting from fibrosis development, which is a sequel and disabling feature of the disease. The rPb27 protein has been studied for prophylactic and therapeutic treatment against PCM. Previous studies from our laboratory have shown a protective effect of rPb27 against PCM. However, these studies have not determined whether rPb27 immunization prevents lung fibrosis. We therefore conducted this study to investigate fibrosis resulting from infection by Paracoccidioides brasiliensis in the lungs of animals immunized with rPb27. Animals were immunized with rPb27 and subsequently infected with a virulent strain of P. brasiliensis. Fungal load was evaluated by counting colony-forming units, and Masson's trichrome staining was performed to evaluate fibrosis at 30 and 90 days post-infection. The levels of CCR7, active caspase 3, collagen and cytokines were analyzed. At the two time intervals mentioned, the rPb27 group showed lower levels of fibrosis on histology and reduced levels of collagen and the chemokine receptor CCR7 in the lungs. CCR7 was detected at higher levels in the control groups that developed very high levels of pulmonary fibrosis. Additionally, the immunized groups showed high levels of active caspase 3, IFN-γ, TGF-β and IL-10 in the early phase of P. brasiliensis infection. Immunization with Pb27, in addition to its protective effect, was shown to prevent pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25487973     DOI: 10.1007/s11046-014-9815-8

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  39 in total

Review 1.  An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.

Authors:  A Giulietti; L Overbergh; D Valckx; B Decallonne; R Bouillon; C Mathieu
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.

Authors:  Dante J Marciani
Journal:  Drug Discov Today       Date:  2003-10-15       Impact factor: 7.851

3.  Increased apoptosis during the early phase of experimental paracoccidioidomycosis as a phenotypic marker of resistance.

Authors:  Maurício A Verícimo; Karla Marcelino França; Andrea C V Arnholdt; Thereza L Kipnis
Journal:  Microbes Infect       Date:  2006-09-20       Impact factor: 2.700

4.  Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis.

Authors:  N W Lukacs; C Hogaboam; S W Chensue; K Blease; S L Kunkel
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

5.  Immunological basis for the gender differences in murine Paracoccidioides brasiliensis infection.

Authors:  Camila Figueiredo Pinzan; Luciana Pereira Ruas; Anália Sulamita Casabona-Fortunato; Fernanda Caroline Carvalho; Maria-Cristina Roque-Barreira
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

6.  Impairment of cellular but not humoral immune responses in chronic pulmonary and disseminated paracoccidioidomycosis in mice.

Authors:  E Castaneda; E Brummer; D Pappagianis; D A Stevens
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

Review 7.  Paracoccidioidomycosis: an update.

Authors:  E Brummer; E Castaneda; A Restrepo
Journal:  Clin Microbiol Rev       Date:  1993-04       Impact factor: 26.132

8.  Pulmonary paracoccidioidomycosis in resistant and susceptible mice: relationship among progression of infection, bronchoalveolar cell activation, cellular immune response, and specific isotype patterns.

Authors:  L E Cano; L M Singer-Vermes; C A Vaz; M Russo; V L Calich
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Cytokine induction in human coccidioidomycosis.

Authors:  D P Dooley; R A Cox; K L Hestilow; M J Dolan; D M Magee
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

Review 10.  Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis.

Authors:  David M Habiel; Cory Hogaboam
Journal:  Front Pharmacol       Date:  2014-01-23       Impact factor: 5.810

View more
  6 in total

Review 1.  PARACOCCIDIOIDOMYCOSIS: CHALLENGES IN THE DEVELOPMENT OF A VACCINE AGAINST AN ENDEMIC MYCOSIS IN THE AMERICAS.

Authors:  Carlos P Taborda; M E Urán; J D Nosanchuk; L R Travassos
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-09       Impact factor: 1.846

Review 2.  PARACOCCIDIOIDOMYCOSIS TREATMENT.

Authors:  Maria Aparecida Shikanai-Yasuda
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-09       Impact factor: 1.846

3.  Recombinant vaccines of a CD4+ T-cell epitope promote efficient control of Paracoccidioides brasiliensis burden by restraining primary organ infection.

Authors:  Rodrigo Assunção Holanda; Julián Esteban Muñoz; Lucas Santos Dias; Leandro Buffoni Roque Silva; Julliana Ribeiro Alves Santos; Sthefany Pagliari; Érica Leandro Marciano Vieira; Tatiane Alves Paixão; Carlos Pelleschi Taborda; Daniel Assis Santos; Oscar Bruña-Romero
Journal:  PLoS Negl Trop Dis       Date:  2017-09-22

4.  Secreted aspartyl proteinase (PbSap) contributes to the virulence of Paracoccidioides brasiliensis infection.

Authors:  Daniele Gonçalves Castilho; Alison Felipe Alencar Chaves; Marina Valente Navarro; Palloma Mendes Conceição; Karen Spadari Ferreira; Luiz Severino da Silva; Patricia Xander; Wagner Luiz Batista
Journal:  PLoS Negl Trop Dis       Date:  2018-09-27

Review 5.  Paracoccidioides-host Interaction: An Overview on Recent Advances in the Paracoccidioidomycosis.

Authors:  Haroldo C de Oliveira; Patrícia A Assato; Caroline M Marcos; Liliana Scorzoni; Ana C A de Paula E Silva; Julhiany De Fátima Da Silva; Junya de Lacorte Singulani; Kaila M Alarcon; Ana M Fusco-Almeida; Maria J S Mendes-Giannini
Journal:  Front Microbiol       Date:  2015-11-25       Impact factor: 5.640

Review 6.  Current trends to control fungal pathogens: exploiting our knowledge in the host-pathogen interaction.

Authors:  Laura C García-Carnero; Luis A Pérez-García; José A Martínez-Álvarez; Juana E Reyes-Martínez; Héctor M Mora-Montes
Journal:  Infect Drug Resist       Date:  2018-07-03       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.